{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-062780","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.699629+00:00","generated_at":"2026-06-12T07:33:16.394202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025","bullets":["Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022","Cash, equivalents $80.4M; expected to fund operations into 2025","R&D expenses $7.2M, up from $3.1M YoY on TARA-002 clinical costs","Preliminary TARA-002 NMIBC expansion results expected 1H24; ADVANCED-2 and LM trial start 4Q23"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-062780","json":"https://secwatch.observer/filing/0001213900-23-062780.json","markdown":"https://secwatch.observer/filing/0001213900-23-062780.md","text":"https://secwatch.observer/filing/0001213900-23-062780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/ea182633-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:33:16.394202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c6941d6ce2c7517a4bdc3ae20016a3deb418d28","claim":"Protara Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $11.3 million, or $1.00 per share, EPS $1.00 per share.","evidence_excerpt":"For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $11.3 million, or $1.00 per share"},{"label":"EPS","value":"$1.00 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}